Effects Of Icariin On Bone Strength, Bone Microstructure, BGP In The Serum And Fabp4mRNA In Treating Postmenopausal Osteoporosis

Objective:By researching mechanism action of Icariin for treating postmenopausal osteoporosis,to explore the possible relationship with BGP in the serum and the target gene Fabp4mRNA. Provide the ICA experimental data for treating PMOP.Methods:1.70female SD rats were adaptably fed for a week, then randomly divided into shamoperation group (20rats) and operation group (50rats). Cut off bilateral ovaries inthe operation group.Sham operation group is only resected abdomen.16weeks later,test bone mineral density by dual energy X-ray absorption method. Including thefemur, the fourth and fifth lumbar.To determin osteoporosis model is successfullyestablished.2. After the model is builed successfully, the operation group is divided into the druggroup and the model group.The drug group was fed icariin(125mg/kg·d).The shamoperation group and model group are given the same amount of sodium carboxysoluble fiber (1mL).Feed6days a week and rest one day, gavage12weeks.3. Using biological mechanics experiment method (the left femur three points bendingtest and the forth lumbar compressing test), to test the bone strength.4. Using Micro CT to scan the femur and the fifth lumbar (select6samples randomlyfrom each group). Get different section pictures from one sample.Through3Dreconstruction of bone tissue with MicroView quantitative analysis software. Theanalysis parameters include bone volume（mm3）, the trabecular thickness（um）, theseparation of trabecular（um）, the number of trabecular（n）.5. Using ELISA to detect the content of BGP in the serum(ng/L).6. Using HE to observe each group’s pathological structure.7. Using qPCR to detect Fabp4mRNA. 8. Using SPSS19.0statistical software to analyse statistical results.Results:1. The body weight of the OVX group is significantly higher than the control group(P＜0.05).2.16weeks later, the OVX group’s bone mineral density is obviously lower than thecontrol group(P＜0.05).3. Compared with the model group and the sham group after being given icriin,biomechanics showed that the drug group’s bone strength is higher (P＜0.05).4. Micro CT result show that bone density of the drug group is higher than modelgroup and the sham group(P＜0.05).5. The drug group’s osteocalcin content in serum is higher than the model group andthe sham group(P＜0.05).6. Fabp4mRNA gene expression of the drug group is lower than the model group(P＜0.05).7. HE staining shows that icriin makes the trabecular thicker and the bone seperaitonsmaller.Conclusion:1. Lacking of estrogen may lead to obesity and osteoporosis.2. Icriin can resist OP by increasing BMD, improving bone strength and changing bonemicrostructure.3. Icriin resists PMOP possibly by improving osteocalcin in the serum, inhibitingFabp4gene expression to inhibit MSCs lipid differentiation, induce osteogeneticdifferentiation.